Abstract: Disclosed herein are compositions comprising high molecular weight heparin. The compositions comprise an effective amount of high molecular weight heparin having an average molecular weight from about 20 kDa to about 40 kDa and having a purity of at least 50%, and a pharmaceutically acceptable excipient. Disclosed herein are also methods of treating eosinophil-related inflammation in a subject.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.

Abstract: Disclosed are methods of detecting eosinophil degranulation in the respiratory tract of subjects. Also, disclosed are methods of producing medical images of the respiratory tract of subjects. The method can include administering radiolabeled heparin to the respiratory tract of subjects, wherein the radiolabeled heparin binds to one or more eosinophil granule protein in the mucosal tissue of the respiratory tract.

Abstract: The present disclosure relates to methods for expressing human insulin derivative in which the motif Leucine-Proline-X-Threonine appears at end of B-chain, where X is any amino acid residue. Said human insulin derivative is expressed using insulin derivative peptide and sortase. The method is to translate a nucleotide sequence encoding a single chain peptide into a precursor of human insulin derivative and combine the single chain peptide with sortase to convert a human insulin derivative precursor into a fully folded, biologically active human insulin derivative.

Abstract: The present invention relates to insulin derivatives which, in comparison to insulin glulisine and similar derivatives, has a simplified process for synthesis. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which the motif Leucine-Proline-X-Threonine appears at the end of the B-chain, where X is any amino acid residue. Due to the nature of the process, the A-chain and B-chain must begin with a Glycine amino acid residue.

Abstract: The present invention relates to insulin derivatives which, in comparison to insulin glulisine and similar derivatives, has a simplified process for synthesis. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which the motif Leucine-Proline-X-Threonine appears at the end of the B-chain, where X is any amino acid residue. Due to the nature of the process, the A-chain and B-chain must begin with a Glycine amino acid residue.

Abstract: Also disclosed are methods

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.

Abstract: The present invention relates to insulin derivatives which, in comparison to insulin glulisine and similar derivatives, has a simplified process for synthesis. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which the motif Leucine-Proline-X-Threonine appears at the end of the B-chain, where X is any amino acid residue. Due to the nature of the process, the A-chain and B-chain must begin with a Glycine amino acid residue.

Abstract: Described herein are various principles related to collecting and analyzing fertility data for female humans. The underlying concept is that a woman's hormones fluctuate throughout the menstrual cycle, affecting optimal exercise routines and general health practices. A dedicated sensor may be used to collect fertility data, or an estimate may be derived from the individual's menstrual history. Once collected or estimated, the fertility data is factored with other variables to determine the optimal exercise routine or general health habits for the woman. The recommendations are communicated to the woman, who may provide feedback to further improve future recommendations.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagitis or other organs in a subject.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagitis or other organs in a subject.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.

Abstract: A method includes determining a total forward power using a frequency domain version of a forward signal transmitted over a cable/connector system to one or more antennas. The method includes determining a total reflected power using a frequency domain version of a reflected signal including a reflected version of the forward signal. The method also includes determining a condition of the cable/connector system using the total forward power and the total reflected power. The method may include determining an estimated reflection coefficient based on the total forward power and the total reflected power and associating the estimated reflection coefficient with the condition of the cable/connector system. Apparatus, program products, and software are also disclosed.

Abstract: A method includes accessing sets of correlation values, each set corresponding to a correlation performed between a number of first samples and a same number of second samples. The sets of correlation values were determined by aligning the number of the first samples with selected second samples and sliding the number of first samples across the second samples to select different sets of the second samples. The first samples are samples of a forward signal transmitted over a cable/connector system to one or more antennas, and the second samples are samples of a reflected RF signal that comprises a reflected version of the forward signal. The method includes determining a maximum value from the plurality of sets of correlation values, and associating the maximum value with a return loss of the cable/connector system. Apparatus, computer programs, and program products are also disclosed.

Abstract: A method includes determining a total forward power using a frequency domain version of a forward signal transmitted over a cable/connector system to one or more antennas. The method includes determining a total reflected power using a frequency domain version of a reflected signal including a reflected version of the forward signal. The method also includes determining a condition of the cable/connector system using the total forward power and the total reflected power. The method may include determining an estimated reflection coefficient based on the total forward power and the total reflected power and associating the estimated reflection coefficient with the condition of the cable/connector system. Apparatus, program products, and software are also disclosed.

Abstract: A method includes accessing sets of correlation values, each set corresponding to a correlation performed between a number of first samples and a same number of second samples. The sets of correlation values were determined by aligning the number of the first samples with selected second samples and sliding the number of first samples across the second samples to select different sets of the second samples. The first samples are samples of a forward signal transmitted over a cable/connector system to one or more antennas, and the second samples are samples of a reflected RF signal that comprises a reflected version of the forward signal. The method includes determining a maximum value from the plurality of sets of correlation values, and associating the maximum value with a return loss of the cable/connector system. Apparatus, computer programs, and program products are also disclosed.

Abstract: Disclosed are compositions and methods for related to echogenic contrast agents. Also disclosed are methods and compositions for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for producing a medical image of a tissue. Also disclosed are methods of monitoring the progression of eosinophilic esophagitis in a subject before, during, and after treatment.

Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.